The Effect of Ciprofloxacin on Prostate-Specific Antigen (PSA)

Authors

  • Andre Dwi Gustiano Medical School of Andalas University, Padang, West Sumatra, Indonesia; Dr. M. Djamil Hospital, Padang, West Sumatra, Indonesia
  • Alvarino Alvarino Medical School of Andalas University, Padang, West Sumatra, Indonesia; Dr. M. Djamil Hospital, Padang, West Sumatra, Indonesia
  • Etriyel MYH Medical School of Andalas University, Padang, West Sumatra, Indonesia; Dr. M. Djamil Hospital, Padang, West Sumatra, Indonesia
  • Peri Eriad Yunir Medical School of Andalas University, Padang, West Sumatra, Indonesia; Dr. M. Djamil Hospital, Padang, West Sumatra, Indonesia

DOI:

https://doi.org/10.55324/ijoms.v2i2.279

Keywords:

PSA, antibiotics, prostate cancer, prostatitis

Abstract

Increased PSA levels can be caused by prostate cancer, prostate infection, and BPH. Several studies report that the use of antibiotics can affect PSA levels. This study aims to determine the effect of ciprofloxacin administration in patients with prostate-specific antigen values ??of 4-10 ng/mL. This was an analytical study with a prospective cohort design. This study was conducted at Dr. M. Djamil Hospital, Padang starting from July 2022 until October 2022. The sampling technique used non-probability sampling with consecutive sampling method. The patient was given the antibiotic ciprofloxacin 2x500 mg for 2 weeks. PSA measurements were carried out before and after administration of antibiotics. There were 20 subject with an average age of 62.65 years (52-79). The mean of initial PSA value was 6.53 ng/mL and the final PSA value was 5.76 ng/mL. There was a significant difference between PSA levels before and after administration of ciprofloxacin (p=0.000). The use of antibiotics in patients with PSA levels of 4-10 ng/ml can reduce PSA levels.

References

al Jalham, K., Younes, N., Badawi, A., Khalafalla, K., & Majzoub, A. (2016). Antibiotics for elevated prostate specific antigen: Where do we stand? Urological Science, 27(3), 154–157. https://doi.org/10.1016/j.urols.2016.05.314

American Cancer Society. (n.d.). Key statistics for prostate cancer. Retrieved October 15, 2022, from https://www.cancer.org

Atalay, H. A., Canat, L., Alkan, ?., Çakir, S. S., & Altunrende, F. (2017). Prostate-specific antigen reduction after empiric antibiotic treatment does not rule out biopsy in patients with lower urinary tract symptoms: prospective, controlled, single-center study. Prostate International, 5(2), 59–64. https://doi.org/10.1016/j.prnil.2017.03.003

Buddingh, K. T., Maatje, M. G. F., Putter, H., Kropman, R. F., & Pelger, R. C. M. (2018). Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review. Canadian Urological Association Journal, 12(1), E25–E30. https://doi.org/10.5489/cuaj.4515

David, M. K., & Leslie, S. W. (2022). Prostate specific antigen. NCBI Bookshelf, 1–6.

Duffy, M. J. (2020). Biomarkers for prostate cancer: Prostate-specific antigen and beyond. Clin Chem Lab Med, 58(3), 326–339.

Fandella, A., Benvenuto, S., Guidoni, E., Giampaoli, M., & Bertaccini, A. (2014). Empiric antibiotics therapy for mildly elevated prostate specific antigen: Helpful to avoid unnecessary biopsies? Archivio Italiano Di Urologia e Andrologia, 86(3), 202–204. https://doi.org/10.4081/aiua.2014.3.202

Gandaglia, G., Albers, P., Abrahamsson, P. A., Briganti, A., Catto, J. W. F., Chapple, C. R., Montorsi, F., Mottet, N., Roobol, M. J., Sønksen, J., Wirth, M., & van Poppel, H. (2019). Structured population-based prostate-specific antigen screening for prostate cancer: The European association of urology position in 2019. European Urology, 76(2), 142–150. https://doi.org/10.1016/j.eururo.2019.04.033

H, K. M., Mehta, N. H., Babu, M., Bansal, D., Mehta, S., Pillai, B. S., & Sam, M. P. (2017). Can antibiotic therapy avoid unnecessary biopsy in males with marginally elevated PSA levels?? X(2), 66–70.

Kanani, S., Mujtaba, N., & Sadler, P. (2021). Acute and chronic prostatitis. InnovAiT: Education and Inspiration for General Practice, 14(1), 33–37. https://doi.org/10.1177/1755738020966359

Karakose, A., Bilgehan Yuksel, M., Pirincci, N., Gorgel, S. N., Atesci, Y. Z., & Gumus, B. (2015). The effect of antibiotherapy on high serum PSA levels. In Eastern Journal of Medicine (Vol. 20).

Karakose, A., Yuksel, M. B., Pirincci, N., Gorgel, S. N., Atesci, Y. Z., & Gumus, B. (2015). The effect of antibiotherapy on high serum PSA levels. Eastern Journal of Medicine, 20(1), 30–33.

Khan, F. U., Ihsan, A. U., Khan, H. U., Jana, R., Wazir, J., Khongorzul, P., Waqar, M., & Zhou, X. (2017). Comprehensive overview of prostatitis. Biomedicine and Pharmacotherapy, 94, 1064–1076. https://doi.org/10.1016/j.biopha.2017.08.016

Leslie, S. W., Soon-Sutton, T. L., Sajjad, H., & Siref., L. E. (2022). Prostate cancer. StatPearls.

Matsushita, M., Fujita, K., & Nonomura, N. (2020). Influence of diet and nutrition. Int J Med Sci, 21, 1–18. https://doi.org/10.4155/EBO.13.494

Moradi, A., Srinivasan, S., Clements, J., & Batra, J. (2019). Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer and Metastasis Reviews, 38(3), 333–346. https://doi.org/10.1007/s10555-019-09815-3

Nordström, T., Akre, O., Aly, M., Grönberg, H., & Eklund, M. (2018). Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases, 21(1), 57–63. https://doi.org/10.1038/s41391-017-0024-7

Özman O, & Talat Z. (2019). New parameters in evaluation of PSA decrease after antibiotherapy; PSA half-life and PSA-ENT. International Archives of Urology and Complications, 5(1). https://doi.org/10.23937/2469-5742/1510054

Pernar, C. H., Ebot, E. M., Wilson, K. M., & Mucci, L. A. (2018). The epidemiology of prostate cancer. Cold Spring Harbor Perspectives in Medicine, 8(12). https://doi.org/10.1101/CSHPERSPECT.A030361

Putra, I. B. O. W., Hamid, A. R. A. H., Mochtar, C. A., & Umbas, R. (2016). Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate International, 4(2), 43–48. https://doi.org/10.1016/j.prnil.2016.03.002

Rajakumari, S. N., Arasi, K. v, & Anandan, H. (2019). Serum prostate-specific antigen following antibiotics in symptomatic patients with lower urinary tract symptoms. In International Journal of Scientific Study (Vol. 32, Issue 1). www.ijss-sn.com

Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021). Prostate cancer. Nature Reviews Disease Primers, 7(1). https://doi.org/10.1038/s41572-020-00243-0

Serretta, V., Catanese, A., Daricello, G., Liotta, R., Allegro, R., Martorana, A., Aragona, F., & Melloni, D. (2008). PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer and Prostatic Diseases, 11(2), 148–152. https://doi.org/10.1038/sj.pcan.4500996

Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G., & De Marzo, A. M. (2018). The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews Urology, 15(1), 11–24. https://doi.org/10.1038/nrurol.2017.167

Siegel, D. A., O’Neil, M. E., Richards, T. B., Dowling, N. F., & Weir, H. K. (2020). Prostate cancer incidence and survival, by stage and race/ethnicity — United States, 2001–2017. MMWR. Morbidity and Mortality Weekly Report, 69(41), 1473–1480. https://doi.org/10.15585/mmwr.mm6941a1

Taha, D. E., Aboumarzouk, O. M., Koraiem, I. O., & Shokeir, A. A. (2020). Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review. Arab Journal of Urology, 18(1), 1–8. https://doi.org/10.1080/2090598X.2019.1677296

Toktas, G., Demiray, M., Erkan, E., Kocaaslan, R., Yucetas, U., & Unluer, S. E. (2013). The effect of antibiotherapy on prostate-specific antigen levels and prostate biopsy results in patients with levels 2.5 to 10 ng/mL. Journal of Endourology, 27(8), 1061–1067. https://doi.org/10.1089/end.2013.0022

Downloads

Published

2022-11-22

Issue

Vol. 2 No. 2 (2022): Indonesian Journal of Multidisciplinary Science

Section

Articles

License

Copyright (c) 2022 Andre Dwi Gustiano, Alvarino Alvarino, Etriyel MYH, Peri Eriad Yunir

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.